Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple endocrine neoplasia type 2.

Michael E Gertner1, Electron Kebebew

  • 1Department of Surgery, University of California San Francisco, 1600 Divisadero Street, C3-47, San Francisco, CA 94115, USA.

Current Treatment Options in Oncology
|July 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRISPR-Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer.

Molecular carcinogenesis·2026
Same author

Workforce growth without reach: National trends in access to high-volume parathyroid surgeons.

Surgery·2026
Same author

Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage.

Endocrine-related cancer·2026
Same author

Utilization of thyroid ultrasound and surgery after glucagon-like peptide-1 receptor agonist prescription.

Surgery·2026
Same author

Dual targeting of BRAF<sup>V600E</sup> and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.

Journal of experimental & clinical cancer research : CR·2026
Same author

Corrigendum to "Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis" [Cancer Letters 633 (2025) 217990].

Cancer letters·2025
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Multiple endocrine neoplasia type 2 (MEN-2) is caused by RET gene mutations. Genetic testing guides prophylactic thyroidectomy and treatment for MEN-2 patients, improving outcomes.

Area of Science:

  • Endocrinology and Genetics
  • Hereditary Cancer Syndromes
  • Oncology

Background:

  • Multiple Endocrine Neoplasia type 2 (MEN-2) is an autosomal dominant hereditary syndrome.
  • MEN-2 encompasses MEN-2A, MEN-2B, and familial medullary thyroid cancer (MTC).
  • Germline mutations in the RET proto-oncogene are the underlying cause in 99% of MEN-2 cases.

Purpose of the Study:

  • To highlight the importance of genotype-phenotype correlations in MEN-2 management.
  • To guide screening strategies for at-risk individuals and carriers of RET mutations.
  • To inform treatment decisions for patients with MEN-2 and related conditions.

Main Methods:

  • Genetic testing to identify germline RET mutations in patients and families.
  • Phenotypic assessment to correlate specific RET mutations with clinical manifestations.

Related Experiment Videos

  • Surgical interventions including prophylactic thyroidectomy, adrenalectomy, and parathyroidectomy.

    • Main Results:

    • RET germline mutations are identified in 99% of MEN-2 cases.
    • Phenotypic variation in MEN-2 is linked to specific RET proto-oncogene mutations.
    • Prophylactic thyroidectomy timing is determined by RET genotype risk stratification.

    Conclusions:

    • Genetic screening for RET mutations is crucial for early diagnosis and management of MEN-2.
    • Tailoring surgical timing, particularly thyroidectomy, based on RET genotype improves patient outcomes.
    • Comprehensive management strategies are essential for addressing MTC, pheochromocytoma, and hyperparathyroidism in MEN-2 patients.